Vanda Pharmaceuticals | VNDA - Operating Expenses


Vanda Pharmaceuticals reported $-1.14B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
AstraZeneca USD 11.55B 674M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 606.26M 79.46M Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Ligand Pharmaceuticals USD 94.5M 39.4M Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.18B 223M Sep/2026
Novartis USD 13.19B 3.9B Sep/2026
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.51B 598M Sep/2026
Takeda JPY 981.78B 36.71B Sep/2026
Teva Pharmaceutical Industries USD 3.18B 733M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025
Veracyte USD 133.73M 7.37M Sep/2026